Events & Presentations

Ablynx organises webcasts for analysts and investors on the occasion of financial results publications and product specific news. In addition, the Company’s presentations at investor conferences are often webcasted and made available for the broader public.

Upcoming IR Events

J.P. Morgan 2018 Healthcare Conference
8-11 January 2108 - San Francisco (CA), USA

Degroof Petercam Healthcare Seminar
1 February 2018 - Brussels, Belgium

Credit Suisse 2018 London Healthcare Conference
17-28 February 2018 - London, UK

Recent IR Presentations

Webcast - Additional data from the Phase III HERCULES study of caplacizumab in aTTP, following ASH late-breaking data
12 December 2017

Click here to replay the webcast

pdf version of the presentation

Jefferies 2017 London Healthcare Conference
15-16 November 2017 - London, UK

Click here to replay the webcast

pdf version of the presentation

Webcast presentation - Ablynx announced positive topline results from the Phase III HERCULES study with caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)
2 October 2017

Click here to replay the webcast

pdf version of the presentation

Annual BAML Healthcare Conference
13-15 September 2017 - London, UK

pdf version of the presentation

Ablynx announced its 2017 half year financial results with webcast
24 August 2017

Click here to replay the webcast

pdf version of the presentation

Ablynx's 2016 full year results webcast
23 February 2017

Click here to replay the webcast

pdf version of the presentation

Webcast presentatie - vobarilizumab, a novel best-in-class anti-IL-6R drug candidate for the treatment of RA
20 oktober 2016

Click here to replay the webcast

pdf version of the presentation

Upcoming Scientific Events

59th Annual ASH meeting
9-12 December 2017 - Atlanta (GA), USA

1st Immunotherapies for infectious Diseases Congress
11-12 December 2017 - Lyon, France

Antibody Engineering & Therapeutics
11-15 December 2017 - San Diego (CA), USA

17th Annual PepTalk: The Protein Science Week
8-12 January 2018 - San Diego (CA), USA

Recent Scientific Presentations

"Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura", presented by Professor Marie Scully in the late-breaking abstracts session at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, USA
12 December 2017 - Atlanta (GA), USA

pdf version of the presentation

Poster "Results of a Phase 2b Study of Vobarilizumab, an Anti-Interleukin 6 Receptor Nanobody®, as Monotherapy in Patients with Moderate-to-Severe Rheumatoid Arthritis" presented at the European Congress of Rheumatology (EULAR)
14-17 June 2017 - Madrid, Spain

pdf version of the presentation

Presentation "Remission and Maintenance of Efficacy in a Phase 2b study of Vobarilizumab, an Anti-Interleukin 6 Receptor Nanobody®, in Patients with Moderate-to-Severe Rheumatoid Arthritis despite Treatment with Methotrexateat" presented at the European Congress of Rheumatology (EULAR)
14-17 June 2017 - Madrid, Spain

pdf version of the presentation

Poster "Impact of caplacizumab treatment on mortality and major thromboembolic events in acquired TTP: Phase II TITAN study results" presented at the 21st European Hemathology Association Congress
9 June 2016 - Copenhagen, Denmark

pdf version of the presentation

Nanobodies as a Versatile Approach for Developing Next Generation Immunotherapies
26 January 2016 - Washington (DC), USA

pdf version of the presentation

Shareholders' Clubs
at
Ablynx

Individual investors can meet with the Ablynx management team at Ablynx’s Quarterly Shareholders’ Clubs organised at Ablynx.

The next events in Dutch will take place on:

7 March 2018 at 5.30pm
23 May 2018 at 5.30pm
26 September 2018 at 5.30pm
5 December 2018 at 5.30pm

To attend an event, please register via email: investors@ablynx.com, mentioning your name and preferred day.

Please click here to download the presentation of the most recent shareholders' club.